Amneal Pharmaceuticals, Inc. (AMRX)
USD 7.69
(-4.71%)
USD 7.69
(-4.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.45 Billion USD | -3.84% |
| 2022 | 3.59 Billion USD | 0.5% |
| 2021 | 3.57 Billion USD | -2.41% |
| 2020 | 3.66 Billion USD | 10.3% |
| 2019 | 3.31 Billion USD | -3.97% |
| 2018 | 3.45 Billion USD | 101.25% |
| 2017 | 1.71 Billion USD | 23.14% |
| 2016 | 1.39 Billion USD | 16.14% |
| 2015 | 1.2 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.51 Billion USD | 1.18% |
| 2024 Q1 | 3.47 Billion USD | 0.59% |
| 2023 Q3 | 3.49 Billion USD | -0.63% |
| 2023 Q2 | 3.51 Billion USD | 1.55% |
| 2023 FY | 3.45 Billion USD | -3.84% |
| 2023 Q1 | 3.46 Billion USD | -3.51% |
| 2023 Q4 | 3.45 Billion USD | -1.23% |
| 2022 Q4 | 3.59 Billion USD | -6.78% |
| 2022 Q3 | 3.85 Billion USD | 0.03% |
| 2022 Q2 | 3.85 Billion USD | 10.6% |
| 2022 FY | 3.59 Billion USD | 0.5% |
| 2022 Q1 | 3.48 Billion USD | -2.55% |
| 2021 Q4 | 3.57 Billion USD | -0.52% |
| 2021 Q1 | 3.59 Billion USD | -1.85% |
| 2021 Q2 | 3.63 Billion USD | 1.1% |
| 2021 FY | 3.57 Billion USD | -2.41% |
| 2021 Q3 | 3.59 Billion USD | -1.14% |
| 2020 Q3 | 3.68 Billion USD | 0.1% |
| 2020 Q1 | 3.98 Billion USD | 20.13% |
| 2020 Q4 | 3.66 Billion USD | -0.77% |
| 2020 FY | 3.66 Billion USD | 10.3% |
| 2020 Q2 | 3.68 Billion USD | -7.56% |
| 2019 Q2 | 3.51 Billion USD | -2.01% |
| 2019 FY | 3.31 Billion USD | -3.97% |
| 2019 Q4 | 3.31 Billion USD | 0.33% |
| 2019 Q3 | 3.3 Billion USD | -5.82% |
| 2019 Q1 | 3.58 Billion USD | 3.72% |
| 2018 Q4 | 3.45 Billion USD | -5.74% |
| 2018 FY | 3.45 Billion USD | 101.25% |
| 2018 Q3 | 3.66 Billion USD | 1.71% |
| 2018 Q2 | 3.6 Billion USD | 108.68% |
| 2018 Q1 | 1.72 Billion USD | 0.59% |
| 2017 Q3 | 1.66 Billion USD | 0.0% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q4 | 1.71 Billion USD | 3.1% |
| 2017 FY | 1.71 Billion USD | 23.14% |
| 2016 FY | 1.39 Billion USD | 16.14% |
| 2016 Q4 | 1.39 Billion USD | 0.0% |
| 2015 FY | 1.2 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bausch Health Companies Inc. | 27.43 Billion USD | 87.414% |
| Catalent, Inc. | 6.14 Billion USD | 43.852% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -191.208% |
| Elanco Animal Health Incorporated | 8.13 Billion USD | 57.58% |
| Perrigo Company plc | 6.04 Billion USD | 42.85% |
| Teva Pharmaceutical Industries Limited | 35.35 Billion USD | 90.234% |
| Zoetis Inc. | 9.29 Billion USD | 62.856% |